Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113698 · ClinicalTrials.gov registry record · Phase 3
Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation
A Phase 3 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00113698: Clinical Trial Phase 3 study, sponsored by University of Utah.
NCT00113698 is a Phase 3 study that was terminated before completion, run by University of Utah. The registered enrollment target is 5 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00113698, a Phase 3 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of angiotensin converting enzyme inhibition (ACE-I) therapy for the treatment of mitral regurgitation (MR).
Interventions
- OTHER Placebo
- DRUG Enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Why NCT00113698 stopped before completion
NCT00113698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00113698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00113698 about?
NCT00113698 is a clinical study titled "Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation". This study will evaluate the efficacy and safety of angiotensin converting enzyme inhibition (ACE-I) therapy for the treatment of mitral regurgitation (MR).
What is the current status of trial NCT00113698?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2004-12. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00113698?
The interventions under investigation include: Placebo (OTHER), Enalapril (DRUG).
Who is sponsoring clinical trial NCT00113698?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00113698's enrollment target sits among peer trials
5 1997th of 2000 higher than 3 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia